Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Bleomycin
Drug ID BADD_D00280
Description A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin.
Indications and Usage For palliative treatment in the management malignant neoplasm (trachea, bronchus, lung), squamous cell carcinoma, and lymphomas.
Marketing Status Prescription; Discontinued
ATC Code L01DC01
DrugBank ID DB00290
KEGG ID D07535
MeSH ID D001761
PubChem ID 5460769
TTD Drug ID D06UVD
NDC Product Code 61703-323; 0143-9240; 0703-3155; 16714-908; 0409-0332; 61703-332; 16714-886; 0143-9241; 70121-1567; 0703-3154; 0409-0323; 69097-364
Synonyms Bleomycin | Bleomycins | BLEO-cell | BLEO cell | BLEOcell | Bleolem | Bléomycine Bellon | Bellon, Bléomycine | Bleomycin A2 | Bleomycin A(2) | Bleomycin B2 | Bleomycin B(2) | Bleomycin Sulfate | Sulfate, Bleomycin | Bleomycinum Mack | Mack, Bleomycinum | Blenoxane | Blanoxan | Bleomicina
Chemical Information
Molecular Formula C55H84N17O21S3+
CAS Registry Number 11056-06-7
SMILES CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O) OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6 =NC(=CS6)C(=O)NCCC[S+](C)C)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Idiopathic pulmonary fibrosis22.01.02.014; 10.02.01.034--Not Available
Infection11.01.08.002--Not Available
Injury12.01.08.004--Not Available
Interstitial lung disease22.01.02.003; 10.02.01.0330.000625%Not Available
Intestinal obstruction07.13.01.0020.000533%Not Available
Kaposi's sarcoma16.33.02.001; 11.05.17.0010.000139%Not Available
Leukopenia01.02.02.0010.001332%Not Available
Local reaction08.01.03.012--Not Available
Lung infiltration22.01.02.004--Not Available
Malaise08.01.01.003--
Mucosal inflammation08.01.06.002--Not Available
Myalgia15.05.02.001--
Myocardial infarction24.04.04.009; 02.02.02.0070.000417%
Nail discolouration23.02.05.0010.000533%
Nail disorder23.02.05.002--
Nausea07.01.07.001--
Nephropathy toxic20.05.03.002; 12.03.01.010--Not Available
Neuropathy peripheral17.09.03.0030.000533%Not Available
Neutropenia01.02.03.0040.003463%Not Available
Neutrophil count decreased13.01.06.0100.000799%
Oedema14.05.06.010; 08.01.07.0060.000533%Not Available
Pain08.01.08.004--
Pain of skin23.03.03.003--
Pancytopenia01.03.03.0030.000533%Not Available
Papillary thyroid cancer16.24.03.002; 05.02.05.0050.000799%Not Available
Paraesthesia17.02.06.0050.000533%
Periorbital oedema23.04.01.002; 10.01.05.010; 06.08.03.017--
Phlebitis24.05.03.001; 12.02.01.002--
Platelet count decreased13.01.04.0010.001066%
Pleuritic pain22.02.04.008--
The 3th Page    First    Pre   3 4 5 6    Next   Last    Total 6 Pages